+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS)

Antiplatelet therapy vs. anticoagulation in cervical artery dissection: rationale and design of the Cervical Artery Dissection in Stroke Study (CADISS)

International Journal of Stroke 2(4): 292-296

Cervical artery dissection is an important cause of stroke in the young. It can present with local symptoms or stroke/transient ischaemic attacks. Following presentation there is a risk of stroke, particularly in the first month following presentation. The mechanism of stroke is believed to be thromboembolic in the majority of cases. Many clinicians anticoagulate patients with cervical dissection for 3-6 months. This is not evidence based and is supported by a paucity of data and no data from randomised control trials. CADISS is a prospective multicentre randomised-controlled trial in acute (within 7 days of onset) carotid and vertebral artery dissection. Intracerebral artery dissection is excluded. Patients are randomised to antiplatelet therapy (aspirin, dipyridamole or clopidogrel alone or in dual combination) or anticoagulation therapy [heparin followed by warfarin aiming for an International Normalised Ratio (INR) in the range 2-3] for at least 3 months. Treatment is open-label. The primary end-point is ipsilateral stroke or death within 3 months from randomisation. Secondary end-points include any TIA or stroke, major bleeding and presence of residual stenosis at 3 months (>50%). All neuroimaging and serious adverse events will be adjudicated blinded to treatment. An initial feasibility phase of 250 subjects will allow us to determine whether *there are sufficient clinical end-points to provide the power to determine a treatment effect and *adequate numbers of patients can be recruited. The feasibility phase will be continued into a fully powered definitive treatment trial. Initial power calculations based on limited natural history data suggest a sample size of approximately 3000. Sample size calculations will be refined once the frequency of outcome events during the feasibility phase is known.

(PDF emailed within 0-6 h: $19.90)

Accession: 051591147

Download citation: RISBibTeXText

PMID: 18705933

DOI: 10.1111/j.1747-4949.2007.00165.x

Related references

Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results. JAMA Neurology 2019, 2019

Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet. Neurology 14(4): 361-367, 2015

Thrombolysis in cervical artery dissection--data from the Cervical Artery Dissection and Ischaemic Stroke Patients (CADISP) database. European Journal of Neurology 19(9): 1199-1206, 2013

Thrombolysis in Cervical Artery Dissection – Data from the Cervical Artery Dissection and Ischaemic Stroke Patients CADISP database. European Journal of Neurology 19(9): 0-0, 2012

Risk of stroke and recurrent dissection after a cervical artery dissection: a multicenter study. Neurology 61(10): 1347-1351, 2003

Does cervical manipulative therapy cause vertebral artery dissection and stroke?. Neurologist 14(1): 66-73, 2008

Stroke, cerebral artery dissection, and cervical spine manipulation therapy. Journal of Neurology 249(8): 1098-1104, 2002

Anticoagulation in cervical artery dissection. Aktuelle Neurologie 30(4): 180-183, Mai, 2003

Linking Spontaneous Coronary Artery Dissection, Cervical Artery Dissection, and Fibromuscular Dysplasia: Heart, Brain, and Kidneys. Journal of the American College of Cardiology 73(1): 67-69, 2019

We Will Use Antiplatelets As Our First Choice for Prevention of Stroke Recurrence in Cervical Arterial Dissection After Reading CADISS--Will You?. World Neurosurgery 84(5): 1182-1184, 2016

Reperfusion therapy in patients with acute ischaemic stroke caused by cervical artery dissection. Neurologia 2017, 2017

Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 38(9): 2605-2611, 2007

Endovascular therapy versus intravenous thrombolysis in cervical artery dissection ischemic stroke - Results from the SWISS registry. European Stroke Journal 3(1): 47-56, 2019

Is it possible to recognize cervical artery dissection on stroke brain MR imaging? A matched case-control study. Ajnr. American Journal of Neuroradiology 32(5): 869-873, 2011

Increased prevalence of hyperhomocysteinemia in cervical artery dissection causing stroke: a case-control study. Cerebrovascular Diseases 27(3): 241-246, 2009